Patho-Physiological Response of LPS Defective \textit{Brucella abortus} S19Δper in Experimentally Infected Mice

Khushal Singh Solanki\(^1\)*, Salauddin Qureshi\(^2\), Pawan Kumar\(^3\), Monalisa Sahoo\(^3\), M. Saminathan\(^3\), U.K. De\(^4\) and Pallab Chaudhuri\(^5\)

\(^1\)Division of Veterinary Biotechnology, ICAR-Indian Veterinary Research Institute, Izatnagar, Uttar Pradesh, INDIA
\(^2\)Division of Biological Standardization, ICAR-Indian Veterinary Research Institute, Izatnagar, Uttar Pradesh, INDIA
\(^3\)Division of Veterinary Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, Uttar Pradesh, INDIA
\(^4\)Division of Veterinary Medicine, ICAR-Indian Veterinary Research Institute, Izatnagar, Uttar Pradesh, INDIA
\(^5\)Division of Bacteriology and Mycology, ICAR-Indian Veterinary Research Institute, Izatnagar, Uttar Pradesh, INDIA

*Corresponding author: KS Solanki; E-mail: khushal4m@gmail.com

Received: 12 Jan., 2019  Revised: 02 Feb., 2019  Accepted: 06 Feb., 2019

ABSTRACT

Brucellosis is an anthropozoonotic infectious disease in which infected animals pose a threat to humans. This disease has considerable social, economic and international trade importance. Despite past and current efforts to eradicate brucellosis, a large number of new human cases are reported annually worldwide. In this study, patho-physiological response to \textit{Brucella abortus} S19Δper infection in BALB/c mice was assessed in comparison to its parent strain, \textit{B. abortus} S19 and virulent strain, 

\textit{B. abortus} 544. Immunohistochemical analysis confirmed the presence of bacteria in liver and spleen. Comparatively lower serum Aspartate aminotransferase (AST) level and observation of less number of microgranulomas in liver indicated that \textit{B. abortus} S19Δper was less infectious and failed to cause active infection unlike S19 and 544 strain. S19Δper, thus could be a safer vaccine candidate as an alternate to the S19 vaccine strain. Hematological studies indicated clinical manifestation of thrombocytopenia in different \textit{Brucella} infected mice including S19Δper. Therefore, measurement of platelets count and serum AST level may offer as reliable indicators of brucellosis in clinical cases.

Keywords: Brucellosis, perosamine synthetase, lipopolysaccharides, thrombocytopenia, aspartate aminotransferase, microgranuloma

Brucellosis is a global zoonotic disease having potential to cause great economic losses in farm animals and health hazards among human beings. In India, bovine brucellosis incurred losses of 3.4 billion USD per annum (about 20,000 crores INR) (Singh et al., 2015). Infected animals are the source of human brucellosis that affects a sizeable number of people in the world (Moreno and Moriyon, 2006). Therefore, control of animal brucellosis is an essential step to combat infection in human (Radostits et al., 2007). Vaccination is an economic and the only way to control animal brucellosis as stamping out is not a choice in the Indian scenario. The \textit{B. abortus} S19 vaccine (S19) is used for animal vaccination in India and many other countries. Among other drawbacks, S19 strain possesses residual virulence causing abortion in when used in adult animals. In our previous study, a perosamine synthetase deletion (per) mutant of \textit{B. abortus} S19 (S19Δper) has been developed which showed high immunogenicity. S19Δper exhibits intermediate rough phenotype with truncated lipopolysaccharide (LPS) (Lalsiamthara, et al., 2015).

Mouse remains the most widely used experimental animal model for \textit{in-vivo} study of \textit{Brucella} infection (Silva et al., 2011). Brucellosis affects the vital organ such as liver, lung, kidney, heart and spleen, leading to their damage or impairment of their functions according to the stage of infection that is reflected in changing the complete blood counts (CBC) and serum biochemistry profile of infected
animals (Al-Majali, 2005). Various cultural, serological and molecular methods are employed for the diagnosis of brucellosis. The “Gold standard” for the diagnosis of brucellosis is isolation and characterization of the organisms from the infected individual but it is arduous, time-consuming and hazardous to laboratory workers.

The present study was carried out to assess the health status of BALB/c mouse after infection with S19\(\Delta\)per, vaccine strain S19 and virulent \(B.\) \(abortus\) 544 strain (S544). Hematological and serum biochemical parameters along with the histological examination of vital organs were performed to evaluate the extent of infection caused by S19\(\Delta\)per.

**MATERIALS AND METHODS**

**Ethics statement and animals**

Normal, healthy, female BALB/c mice (4-6 weeks) were housed in the institute experimental animal house facility and the animals received water and food \(ad\) \(lib.\) Animal experiments were performed with the approval and following the guidelines of the Institute Animal Ethics Committee (IAEC). \(Brucella\) organisms were handled and processed in accordance to guidelines provided by Institute Biosafety Committee (IBSC), IVRI.

**Mouse inoculation**

\(Brucella\) \(abortus\) strain 544 (S544) was obtained from \(Brucella\) referral laboratory, Division of Veterinary Public Health, IVRI, Izatnagar.

**Table 1:** Bacterial inoculation of BALB/c mice with different \(Brucella\) \(abortus\) strains, S19\(\Delta\)per, S19 and S544 through intraperitoneal (i.p) route

| Sl. No. | Experimental groups | No. of BALB/c mice | Dose and route |
|--------|---------------------|--------------------|---------------|
| 1      | \(B.\) \(abortus\) S19\(\Delta\)per | 6                  | \(5 \times 10^5\) CFU, i.p. |
| 2      | \(B.\) \(abortus\) S19 | 6                  | \(5 \times 10^5\) CFU, i.p. |
| 3      | \(B.\) \(abortus\) strain 544 | 6                  | \(5 \times 10^5\) CFU, i.p. |
| 4      | PBS                 | 6                  | 200 \(\mu\)l, i.p. |

The S19 vaccine strain was obtained from the Division of Biological Products, IVRI. \(Brucella\) organisms were grown on tryptose soya agar (TSA) at 37 °C for 48 hours, suspended in phosphate buffer saline solution, for enumeration of colony-forming-units (CFU). BALB/c mice were randomly segregated into 4 groups. Six mice in each of the three treatment groups were inoculated intraperitoneally (i.p.) with a suspension containing \(5 \times 10^5\) CFU of S19\(\Delta\)per, S19 and S544, respectively (Table 1).

**Blood collection**

Blood was collected from retro-orbital sinus of each mouse on 0 day and 15 days post infection (dpi). Serum was separated by centrifugation at 3000 rpm for 10 min at 4°C in a bench top centrifuge (Eppendorf) and stored at -20 °C till used.

**Necropsy**

All mice were euthanized humanely immediately after blood collection at 15 dpi. Liver, lung, heart, kidney and spleen were fixed in 10% neutral buffered formalin and processed for histopathology. Tissues were embedded in paraffin, sectioned, and mounted on glass slides, and then stained with hematoxylin and eosin (Luna, 1968).

**Immunohistochemistry (IHC)**

Formalin-fixed paraffin-embedded tissue sections of liver and spleen were mounted on poly-L-Lysine (Sigma) pre-coated slides followed by deparaffinization in xylene, rehydration in graded ethanol, and quenching of endoperoxidase activity using 3% \(\text{H}_2\text{O}_2\) in methanol. Antigen retrieval was done in heat mediated antigen retrieval solution according to manufacturer’s instructions (Vector Labs, USA). To block non-specific sites, 2.5% normal non-immune goat serum (Vector Labs, USA) was used. The sections were incubated with rabbit anti-\(Brucella\) serum as primary antibodies followed by goat anti-rabbit IgG (whole molecule)-Peroxidase conjugate (Sigma, USA) and developed using DAB (3,3’-diaminobenzidine tetrahydrochloride) enhanced liquid substrate System (Sigma, USA). Immunostained sections were counterstained with Mayer’s hematoxylin (Sigma, USA) and mounted with a tissue mounting medium (CC/ Mount\(\text{TM}\), Sigma, USA).
Haematology
For DLC (differential leukocyte counts), an EDTA coated blood on clean grease free slide was fixed with methanol and stained with Giemsa stain.

The Complete blood count (CBC) was conducted using ABX Micros ESV60 haem-analyzer (ABX Vet Package, HORIBA ABX Diagnostic, France) immediately after blood collection (Table 2).

Serological tests
Sera samples collected on day 0 and 15 dpi were analyzed for anti-Brucella antibodies using Rose Bengal coloured antigen obtained from the Division of Biological products, IVRI. Rose Bengal Plat agglutination Test (RBPT) assay was performed using a volume of 30 µl of serum and an equal volume of RBPT antigen on a glass slide. Formation of agglutination is indicative of positive reactivity.

Serum biochemistry profile
Serum clinical chemistry profile for albumin, globulin, blood-urea-nitrogen (BUN), cholesterol, creatinine, total protein, triglyceride, glucose, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) was determined by an automated analyzer (Vet Test 8008, IDEXX Laboratories, USA) using IDEXX Vet Test slides.

Statistical analysis
It was performed using IBM SPSS version 20.0 program. The difference in mean values among various experimental groups were compared using one-way ANOVA with Tukey’s HSD test and considered significant at p<0.05.

RESULTS AND DISCUSSION
Hematology
The results of hematological parameters of Brucella inoculated BALB/c mice are presented in Table 2. Thrombocytopenia was observed in all Brucella inoculated groups that was significantly more pronounced in S19Δper infected mice. The S19Δper infected mice showed lymphocytopenia that was significantly more evident in strain 544 infected group. There was a significant difference in the number of lymphocytes and platelets among different infected groups. Neutrophilia was also observed in all infected mice.

Table 2: Hematological parameters (mean ± SE) of BALB/c mice at day 15th post-inoculation

| Sl. No. | Blood parameters | B. abortus strain 544 (n=6) | B. abortus S19 (n=6) | B. abortus S19Δper (n=6) | Healthy (PBS) (n=6) |
|---------|------------------|---------------------------|---------------------|-------------------------|----------------------|
| 1       | RBC (× 10⁶/µl)   | 8.266 ± 0.409a            | 8.621 ± 0.739a      | 9.220 ± 0.125a          | 9.185 ± 0.295a       |
| 2       | Hb (g/dl)        | 14.783 ± 0.681a           | 15.150 ± 1.173a     | 16.133 ± 0.156a         | 16.750 ± 0.240a      |
| 3       | PCV (%)          | 40.350 ± 2.103a           | 42.016 ± 3.916a     | 44.833 ± 0.537a         | 47.350 ± 0.689a      |
| 4       | MCV (fl)         | 49.000 ± 0.447a           | 48.666 ± 0.760a     | 48.500 ± 0.223a         | 51.833 ± 0.726b      |
| 5       | MCH (pg)         | 17.900 ± 0.313a           | 17.683 ± 0.231a     | 17.483 ± 0.107a         | 18.300 ± 0.628a      |
| 6       | MCHC (g/dl)      | 36.683 ± 0.494a           | 36.400 ± 0.679a     | 35.983 ± 0.270a         | 35.316 ± 0.748a      |
| 7       | Platelets (× 10³/µl) | 845.333 ± 28.842a | 816.666 ± 15.79ab   | 729.833 ± 21.097b       | 980.166 ± 27.065c    |
| 8       | WBC (× 10³/µl)   | 16.650 ± 2.293a           | 15.066 ± 1.151a     | 15.033 ± 1.334a         | 14.900 ± 0.970a      |
| 9       | Neutrophils (%)  | 44.333 ± 1.926a           | 43.833 ± 1.904a     | 36.333 ± 3.480a         | 16.833 ± 0.9457b     |
| 10      | Eosinophils (%)  | 0.000 ± 0.0000a           | 0.0000± 0.0000a     | 0.166 ± 0.166a          | 0.166 ± 0.166a       |
| 11      | Basophils (%)    | 0.000 ± 0.0000a           | 0.333 ± 0.210a      | 0.166 ± 0.477a          | 0.333 ± 0.333a       |
| 12      | Lymphocytes (%)  | 50.333±1.282a             | 52.666±2.275ac      | 60.500±3.422a           | 78.500±1.522b        |
| 13      | Monocytes (%)    | 5.333±1.744a              | 3.166±1.514a        | 1.833±0.307a            | 4.166±1.681a         |

Note: Abbreviations: RBC (Red blood cells), Hb (Hemoglobin), PCV (Packed cell volume), MCV (Mean corpuscular volume, MCH (Mean corpuscular hemoglobin), MCHC (Mean corpuscular hemoglobin concentration); Values represent mean ± SE. The mean values were compared between groups by one-way ANOVA followed by Tukey’s HSD (honestly significant difference)-multiple comparison test. Means sharing the similar superscripts in the same row are not significantly different from each other (P<0.05).
Serum biochemical parameters

The analyzed results of various serum biochemical parameters are presented in Table 3. In comparison with healthy animals, aspartate aminotransferase (AST) level was found considerably elevated in Brucella-infected groups. However, the level of AST was considerably lower in the S19Δper group than S544 and S19 infected mice. In addition, the level of blood urea nitrogen (BUN) was observed significantly lower in the S19Δper group than S544 infected mice only. The difference in the concentration of other parameters such as albumin, cholesterol, creatinine, Triglycerides (TRIG), Total protein (TP), ALT, glucose and globulin was found insignificant in the serum of S19Δper group.

Histopathological findings

Liver

Microscopically, the liver of S544 infected BALB/c mice showed extensive infiltration of mononuclear cells around the blood vessels and also in the focal areas in the parenchyma along with macrophages forming microgranuloma like structures. In few animals, the focal areas of hepatic degeneration and necrosis were also seen. The presence of few neutrophils at isolated areas with MNCs was also found in some cases. Similarly, the liver of B. abortus S19 vaccinated BALB/c mice showed minute foci of infiltration in the parenchyma which was characterized by the presence of MNCs and few neutrophils. The liver of mice immunized with S19 showed comparatively less inflammatory changes as compared to the mice infected with S544. Among different experimental group, liver of mice inoculated with S19Δper showed the least number of foci of microgranuloma formation and infiltration of MNCs (Fig. 1).

Table 3: Serum biochemical parameters (mean ± SE) of BALB/c mice at day 15th post-inoculation with 5 × 10⁵ CFU S19Δper, S19 and S544

| Sl. No. | Serum biochemical parameters | B. abortus strain 544 (n=6) | B. abortus S19 (n=6) | B. abortus S19Δper (n=6) | Healthy (PBS) (n=6) |
|--------|-------------------------------|-----------------------------|---------------------|--------------------------|---------------------|
| 1      | BUN (mg/dl)                   | 23.000 ± 1.290a             | 12.750 ± 1.5478b    | 12.250 ± 0.946b          | 11.250 ± 1.108b     |
| 2      | Creatinine (mg/dl)            | 0.375 ± 0.025abc            | 0.400 ± 0.040abc    | 0.275 ± 0.025abc         | 0.250 ± 0.0287c     |
| 3      | Cholesterol (mg/dl)           | 117.250 ± 10.483a           | 74.750 ± 7.110b     | 76.750 ± 4.607b          | 95.500 ± 7.005bc    |
| 4      | AST (U/L)                     | 368.500 ± 7.984a            | 273.250 ± 7.318b    | 214.500 ± 8.026c         | 186.750 ± 2.286d    |
| 5      | ALT (U/L)                     | 57.250 ± 3.966abc           | 71.500 ± 7.762a     | 52.750 ± 5.618abc        | 44.500 ± 6.409bc    |
| 6      | Glucose (mg/dl)               | 133.500 ± 10.935a           | 106.750 ± 15.991a   | 119.250 ± 18.445a        | 124.000 ± 8.784a    |
| 7      | TP (g/dl)                     | 6.775 ± 0.311a              | 5.5750 ± 0.0478b    | 6.300 ± 0.158ab          | 6.425 ± 0.332abc    |
| 8      | TRIG (mg/dl)                  | 100.750 ± 6.896a            | 108.500 ± 6.383a    | 95.750 ± 0.478a          | 96.000 ± 5.802bc    |
| 9      | Albumin (g/dl)                | 2.400 ± 0.147b              | 1.900 ± 0.040a      | 2.250 ± 0.028ab          | 2.425 ± 0.125b      |
| 10     | Globulin (g/dl)               | 4.375±0.179b                | 3.675±0.025b        | 4.075±0.165ab            | 3.975±0.197bc       |

Note: Abbreviations: BUN (Blood urea nitrogen), ALT (Alanine aminotransferase), AST (Aspartate aminotransferase), TP (Total protein), TRIG (Triglycerides); Values represent mean ± SE. The mean values were compared between groups by one-way ANOVA followed Tukey’s HSD (honestly significant difference)-multiple comparison test. Statistical significant difference in mean values between groups are indicated by different superscript letters at p<0.05.

Fig. 1: Histopathology of visceral organs of BALB/c mice at day 15th post-inoculation with 5 × 10⁵ CFU of virulent B. abortus strain 544, B. abortus S19 and B. abortus S19Δper
**Spleen**

Spleen of BALB/c mice infected with strain S544 and S19 revealed non follicular proliferation of the lymphocytes along with macrophages indicating highly reactive spleen. The red pulp was sparsely distributed which was occupied by the lymphocytes in mice spleen. Focal areas also showed the presence of the lympholysis in some cases. Similarly, the spleen of the S19Δper inoculated mice also revealed reactive changes characterized by variable sized lymphocytes (Fig. 1).

**Kidney**

Few focal foci of MNCs infiltration were found in the renal parenchyma and around blood vessels in the S544 infected mice. Some cases also revealed mild degenerative changes in the tubular epithelium. Similar changes were noticed in the S19 and S19Δper inoculated groups but the number of foci was less. (Fig. 1)

The presence of *Brucella* in infected liver and spleen was also confirmed by immunohistochemistry (Fig. 2).

![Fig. 2: Immunohistochemical detection of *Brucella* antigen (Golden brown deposition) in liver and spleen of BALB/c mice at day 15<sup>th</sup> post-inoculation with 5 × 10<sup>5</sup> CFU of virulent *B. abortus* strain 544, *B. abortus* S19 and *B. abortus* S19Δper. Staining of uninfected (control) tissue produced no signal. IHC × DAB ×400](image)

Mouse remains the most suitable experimental animal to investigate *Brucella* infection in-vivo. The results of vaccine testing and infection studies depend upon breed, sex, age, genetic makeup and physiological status of mice, in addition to the virulence, dosage and route of inoculation of *Brucella* strain. Clinicopathological observations and clinical chemistry profile are commonly evaluated in mice as a disease model for biomedical research (Hall, 1992; Irausquin, 1992; Kanno, 1992). To overcome the flaws of the currently used *B. abortus* S19 vaccine, an equally immunogenic LPS defective mutant of S19 (S19Δper) was generated (Lalsiamthara et al., 2015). The authors reported that S19Δper produces intermediate rough colonies due to truncated LPS. Further, it was shown that S19Δper conferred solid immunity against virulent challenge with S544 in a murine model. The present study was carried out to evaluate the safety aspects of S19Δper in-vivo in the murine model. To determine the extent of infection, vital organs of BALB/c mice infected with S19Δper, S19 vaccine and virulent 544 strain, were collected at 15<sup>th</sup> dpi.

![Fig. 3: RBPT on mice sera collected after 15 day on inoculation. BALB/c mice were inoculated with 5 × 10<sup>5</sup> CFU of virulent *B. abortus* strain 544, *B. abortus* S19 and *B. abortus* S19Δper. At day 15<sup>th</sup> post inoculation, S544 and S19 mice strongly reacted with RBPT characterized by the formation of agglutination; S19Δper immunized mice showed RBPT negative results](image)

Extensive microgranulomatous lesions in liver, depletion of red pulp in spleen, MNCs infiltration forming foci in renal parenchyma were characteristics of S544 infection in mice. Pugh et al. (1989) confirmed the depletion of splenic lymphoid tissue in *B. abortus* 2308 infected BALB/c as well as in other strains of mice. Histological findings in liver confirm that *B. abortus* produces granulomatous lesions and acute inflammatory responses in mice (Riglar and Cheers, 1980; Cheers, 1984; Ko et al., 2002a; Ko et al., 2002b). Liver is the first organ exhibiting microgranuloma as an important pathological lesion (Grillo et al., 2012). Granulomas consisted of histiocytic cells mixed with monocytes, lymphoid cells and granulocytes, several of which having ingested *Brucella* antigen (Yoneyama and Ichida, 2005). Granuloma formation localizes the
pathogens which are then easily engulfed by the phagocytic cells. Brucella starts multiplying in the cytoplasm resulting in transformation of phagocytic cells into epithelioid cells. As expected, golden brown deposition as a positive-IHC signal confirmed the presence of Brucella inside granulomas and also support IHC specificity (Fig. 2). The presence of comparatively less number of microgranuloma in the liver and less number of foci in kidney depicts less infectious nature of S19Δper. This property makes S19Δper a more safe vaccine candidate than its parent strain, S19. The attenuated biological activity of S19Δper is attributed to its truncated lipopolysaccharide (LPS) structure.

Lympholysis, as we observed in Brucella inoculated mice spleen was associated with temporally decreased percentage of T and B cells in the spleen (Araya et al., 1989). From circulation, monocytes migrate into tissue and mature into macrophage and dendritic cells. Thus the population of macrophages, that were initially present in small number, rapidly increase as result of the immune or inflammatory cascade. The infiltrated macrophages phagocytosed brucellae facilitated by the deposition of C3b following antibody-independent activation of complement components (Corbeil et al., 1988). The influx of phagocytic cells generates exuberant inflammatory and immune responses leading to the elimination of organisms.

Hematological analysis of S544, S19 and S19Δper inoculated mice on 15th dpi revealed lymphopenia, thrombocytopenia, and neutrophilia. Immune–mediated thrombocytopenia was one of the hematological complications in a case of acute human brucellosis (Hayrettin et al., 1998; Gurkan et al., 2003; Tunccan et al., 2014). The presence of pancytopenia with severe thrombocytopenia in acute brucellosis can imitate several primary hematological diseases (Yilmaz et al., 2007; Erduran et al., 2010). The exact cause of thrombocytopenia in brucellosis is still obscure but it may be due to hypersplenism, disseminated intravascular coagulation, hemophagocytosis, bone marrow suppression, immune destruction of platelets and adherence of thrombocyte to damaged vascular surfaces (Yilmaz et al., 2007; Erduran et al., 2010).

Altered serum enzyme activities are the trusted indicators of pathological changes and not a specific disease. The purpose of studying serum biochemical parameters was to evaluate potential changes in serum enzymes activities and protein fractions in sera of brucellosis-infected mice, which would help in elucidating the pathophysiology of Brucella infection.

In the present study, an increase in AST level was observed in the serum of all Brucella infected mice which are in line with the findings of El-Boshy et al. (2009) in camels, Nath et al. (2014) and Elazab (2015) in Brucella infected cows. Measuring AST level in serum is valuable for detecting liver dysfunction in several types of its disorder, diseases and hepatic injury. In comparison with healthy mice, the AST level in B. abortus S19Δper was higher, but the AST level was significantly lower than S544 and S19 inoculated mice clearly indicate the less deleterious effect of S19Δper on the liver functions which was also reflected in less number of microgranulomas as a pathological lesion (Fig. 1).

CONCLUSION

S19Δper with truncated LPS showed a lower potential to establish infection in mice. This property of attenuation would make S19Δper a more safe vaccine candidate as an alternative to the S19 vaccine. Measuring serum AST level and platelets count may be a complementary assay for diagnosis of brucellosis.

Funding source: This work was supported by Department of Biotechnology, Govt. of India.

Conflicts of interest: None

ACKNOWLEDGEMENTS

We are thankful to the Director, IVRI for providing infrastructural facilities and support in carrying out this research work. We are thankful to the cooperation of auxiliary staff for their help in handling and management of mice, and collection of samples.

REFERENCES

Al-Majali, A.M. 2005. Seroepidemiology of caprine Brucellosis in Jordan. Small Ruminant Research, 58(1): 13-18.

Araya, L.N., Elzer, P.H., Rowe, G.E., Enright, F.M. and Winter, A.J. 1989. Temporal development of protective cell mediated and humoral immunity in BALB/c mice infected with Brucella abortus. J. Immunol., 143(10): 3330-3337.
Cheers, C. 1984. Pathogenesis and cellular immunity in experimental murine brucellosis. *Dev. Biol. Stand.*, 56: 237-246.

Corbeil, L.B., Blau, K., Inzana, T.I., Nielsen, K.H., Jacobson, R.H., Corbeil, R.R. and Winter, A.J. 1988. Killing of *Brucella abortus* by bovine serum. *Infect. Immun.*, 56(12): 3251-3261.

Elazab, M.F.A. 2015. Evaluation of serum enzyme activities and protein fractions in *Brucella*-infected cows. *Turkish J. Vet. Anim. Sci.*, 39(4): 480-484.

EL-Boshy, M., Abbas, H., EL-Khodery, S. and Osman, S. 2009. Cytokine response and clinicopathological findings in *Brucella* infected camels (*Camelus dromedaries*). *Veterinarni Medicina*, 54(1): 25-32.

Erduran, E., Makuloglu, M. and Mutlu, M. 2010. A rare hematological manifestation of brucellosis: reactive hemophagocytic syndrome. *J. Microbiol. Immunol. Infect.*, 43(2): 159-162.

Grillo, M.J., Blasco, J.M., Gorvel, J.P., Moriryon, I. and Moreno, E. 2012. What have we learned from brucellosis in the mouse model? *Vet. Res.*, 43(1): 1-35.

Gurkan, E., Baslamisli, F., Guvenc B., Bozkurt, B. and Unsal, C. 2003. Immune thrombocytopenic purpura associated with brucella and toxoplasma infections. *Am. J. Hematol.*, 74(1): 52-54.

Hall, RL. 1992. Clinical pathology for preclinical safety assessment: current global guidelines. *Toxicol. Pathol.*, 20(3-2): 472-476.

Hayrettin, A., Hasan, I., Tahir, S., Turan, B. and Pekcan, D.A. 1998. Hematological manifestations in Brucellosis cases in Turkey. *Acta Medica Okayama*, 52(1): 63-65.

Irausquin, H. 1992. The value of chemical pathology data in animal screening studies for safety evaluation. *Toxicol. Pathol.*, 20(3-2): 515-518.

Kanno, J. 1992. Clinical pathology testing regulatory concerns. *Toxicol. Pathol.*, 20(3-2): 534-537.

Ko, J., Gendron-Fitzpatrick, A., Ficht, T. A. and Splitter, G. A. 2002a. Virulence criteria for *Brucella abortus* strains as determined by interferon regulatory factor 1- deficient mice. *Infect. Immun.*, 70(12): 7004-7012.

Ko, J., Gendron-Fitzpatrick, A. and Splitter, G. A. 2002b. Susceptibility of IFN regulatory factor-1 and IFN consensus sequence binding protein deficient mice to brucellosis. *J. Immunol.*, 168(5): 2433-2440.

Lalsiamthara, J., Gogiaa, N., Goswami, T.K., Singh, R.K. and Chaudhuri, P. 2015. Intermediate rough *Brucella abortus* S19aper mutant is DIVA enable, safe to pregnant guinea pigs and confers protection to mice. *Vaccine*, 33(22): 2577-2583.

Luna, L.G. 1968. Manual of histologic staining methods of the armed forces institute of pathology. In 3rd edn., McGraw-Hill, New York, NY.

Moreno, E. and Moriyon, I. 2006. The genus *Brucella*. In The Prokaryotes, Edited by Dworkin, M., Falkow, S., Rosenberg, E., Schleifer, K.H. and Stackebrant, E. New York: Springer, Volume 5. Part 1, section 31, pp. 315–456.

Nath, R., Das, S., Sarma, S. and Devi, M. 2014. Comparison of blood profiles between healthy and *Brucella* affected cattle. *Vet. World*, 7(9): 668-670.

Pugh Jr, G.W., Zehr, E.S., Meador, V.P., Phillips, M., McDonald, T.J. and Deyoe, B.L. 1989. Immunologic, histopathologic, and bacteriologic responses of five strains of mice to *Brucella abortus* strain 2308. *Am. J. Vet. Res.*, 50(3): 323-328.

Radostits, O.M., Gay, G.C., Hinchliff, K.W. and Constable, P.D. 2007. Diseases associated with *Brucella* species. In: *Veterinary Medicine: A textbook of the diseases of cattle, horse, sheep, pigs & goat*, Edn.10th, Saunders Ltd., USA, pp. 963-994.

Riglar, C. and Cheers, C., 1980. Macrophage activation during experimental murine brucellosis II. Inhibition of in vitro lymphocyte proliferation by *Brucella* activated macrophages. *Cellular Immunology*, 49(1): 154-167.

Silva, T.M., Costa, E.A., Paixao, T.A., Tsolis, R.M. and Santos, R.L. 2011. Laboratory animal models for brucellosis research. *J. Biomed. Biotechnol.*, article ID 518323: 1-9.

Singh, B.B., Dhand, N.K. and Gill, J.P.S. 2015. Economic losses occurring due to Brucellosis in Indian livestock populations. *Prev. Vet. Med.*, 119(3): 211-215.

Tuncan, O. G., Dizbay, M., Senol, E., Aki, Z. and Ozendemir, K. 2014. Isolated severe immune thrombocytopenia due to acute brucellosis. *Indian J. Hematol. Blood Transfus.*, 30(1): 27-29.

Yilmaz, M., Tiryaki, O., Namiduru, M., Okan, V., Oguz, A., Buyukhatipoglu, H., Karaoglan, I. and Yilmaz, B. 2007. Brucellosis-induced immune thrombocytopenia mimicking ITP: a report of seven cases. *Int. J. L. Hematol.*, 29(6): 442-445.

Yoneyama, H. and Ichida, T. 2005. Recruitment of dendritic cells by bovine serum. *Cellular Immunology*, 246(3): 159–162.
